1h Free Analyst Time
Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2019Speak directly to the analyst to clarify any post sales queries you may have.
Summary
According to the recently published report 'Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2019'; Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) pipeline Target constitutes close to 64 molecules. Out of which approximately 63 molecules are developed by companies and remaining by the universities/institutes.
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - CTLA4 also known as CD152 is a protein receptor found on the surface of T cells. It functions as an immune checkpoint and down regulates the immune system. The affinity of CTLA4 for its natural B7 family ligands, CD80 and CD86, is considerably stronger than the affinity of their cognate stimulatory co-receptor CD28. Inhibition of receptor acts as a major negative regulator of T-cell responses.
The report 'Cytotoxic T Lymphocyte Protein 4 - Pipeline Review, H2 2019' outlays comprehensive information on the Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 8, 17, 1, 25 and 9 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology and Infectious Disease which include indications Solid Tumor, Melanoma, Metastatic Melanoma, Non-Small Cell Lung Cancer, Breast Cancer, Colon Cancer, Gastric Cancer, Renal Cell Carcinoma, Small-Cell Lung Cancer, Colorectal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Cervical Cancer, Metastatic Breast Cancer, Nasopharyngeal Cancer, Squamous Non-Small Cell Lung Cancer, Bladder Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Hepatocellular Carcinoma, Metastatic Colorectal Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Ovarian Cancer, Peritoneal Cancer, Prostate Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Anal Cancer, Bile Duct Cancer (Cholangiocarcinoma), Gastroesophageal (GE) Junction Carcinomas, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Metastatic Renal Cell Carcinoma, Muscle Invasive Bladder Cancer (MIBC), Non-Hodgkin Lymphoma, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Soft Tissue Sarcoma, Anaplastic Thyroid Cancer, Endometrial Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma (ESCC), Germ Cell Tumors, Lung Cancer, Lymphoma, Malignant Pleural Mesothelioma, Medullary Thyroid Cancer, Merkel Cell Carcinoma, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Pancreatic Cancer, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Neuroblastoma, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Osteosarcoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Salivary Gland Cancer, Sarcomas, Triple-Negative Breast Cancer (TNBC), Vaginal Cancer, Vulvar Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Adenoid Cystic Carcinoma (ACC), Adrenal Gland Cancer, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Advanced Malignancy, Basal Cell Carcinoma (Basal Cell Epithelioma), Bone Sarcoma, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Dysgerminoma, Ependymoma, Epstein-Barr Virus (HHV-4) Infections, Ewing Sarcoma, Follicular Thyroid Cancer, Gallbladder Cancer, Germinomatous (Seminomatous) Germ Cell Tumors, Glioblastoma Multiforme (GBM), Gliosarcoma, Graft Versus Host Disease (GVHD), Head And Neck Cancer, Head And Neck Carcinoma, Hematological Tumor, High-Grade Glioma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Kaposi Sarcoma, Leukemia, Liver Cancer, Malignant Fibrous Histiocytoma, Malignant Mesothelioma, Medulloblastoma, Meningioma, Metastatic Biliary Tract Cancer, Metastatic Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Liver Cancer, Metastatic Lung Cancer, Metastatic Ovarian Cancer, Metastatic Prostate Cancer, Metastatic Uveal Melanoma, Non-Small Cell Lung Carcinoma, Nongerminomatous (Nonseminomatous) Germ Cell Tumors, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Papillary Renal Cell Carcinoma, Papillary Thyroid Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Penile Cancer, Primitive Neuroectodermal Tumor (PNET), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Ureter Cancer, Urethral Cancer, Urinary Tract Cancer.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
- The report reviews Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
IntroductionCytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Overview
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Therapeutics Development
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Therapeutics Assessment
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Companies Involved in Therapeutics Development
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Drug Profiles
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Dormant Products
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Discontinued Products
Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Product Development Milestones
Appendix
List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Number of Products under Development by Companies, H2 2019 (Contd..2)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Products under Development by Companies, H2 2019 (Contd..11), H2 2019
Products under Development by Companies, H2 2019 (Contd..12), H2 2019
Products under Development by Companies, H2 2019 (Contd..13), H2 2019
Products under Development by Companies, H2 2019 (Contd..14), H2 2019
Products under Development by Companies, H2 2019 (Contd..15), H2 2019
Products under Development by Companies, H2 2019 (Contd..16), H2 2019
Products under Development by Companies, H2 2019 (Contd..17), H2 2019
Products under Development by Companies, H2 2019 (Contd..18), H2 2019
Products under Development by Companies, H2 2019 (Contd..19), H2 2019
Products under Development by Companies, H2 2019 (Contd..20), H2 2019
Products under Development by Companies, H2 2019 (Contd..21), H2 2019
Products under Development by Companies, H2 2019 (Contd..22), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Abeome Corp, H2 2019
Pipeline by Aduro BioTech Inc, H2 2019
Pipeline by Agenus Inc, H2 2019
Pipeline by Akeso Biopharma Inc, H2 2019
Pipeline by Alligator Bioscience AB, H2 2019
Pipeline by AlphaMab Co Ltd, H2 2019
Pipeline by Alpine Immune Sciences Inc, H2 2019
Pipeline by Anaeropharma Science Inc, H2 2019
Pipeline by Apollomics Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by BeyondSpring Inc, H2 2019
Pipeline by Biocad, H2 2019
Pipeline by Biosortia Pharmaceuticals, H2 2019
Pipeline by BJ Bioscience Inc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Cancure Ltd, H2 2019
Pipeline by Cellective BioTherapy Inc, H2 2019
Pipeline by Cold Genesys Inc, H2 2019
Pipeline by CStone Pharmaceuticals Co Ltd, H2 2019
Pipeline by DotBio Pte Ltd, H2 2019
Pipeline by Five Prime Therapeutics Inc, H2 2019
Pipeline by GigaGen Inc, H2 2019
Pipeline by Harbour BioMed, H2 2019
Pipeline by Hengenix Biotech Inc, H2 2019
Pipeline by Hualan Biological Engineering Inc, H2 2019
Pipeline by Immunocore Ltd, H2 2019
Pipeline by Immunwork Inc, H2 2019
Pipeline by Immutics Inc, H2 2019
Pipeline by Innovent Biologics Inc, H2 2019
Pipeline by Inovio Pharmaceuticals Inc, H2 2019
Pipeline by JHL Biotech Inc, H2 2019
Pipeline by Jiangsu Alphamab Biopharmaceuticals Co Ltd, H2 2019
Pipeline by MacroGenics Inc, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Momenta Pharmaceuticals Inc, H2 2019
Pipeline by Nanjing Jinsirui Biotechnology Co Ltd, H2 2019
Pipeline by OncoImmune Inc, H2 2019
Pipeline by Premier Biomedical Inc, H2 2019
Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
Pipeline by Replimune Ltd, H2 2019
Pipeline by Serometrix LLC, H2 2019
Pipeline by Shanghai Henlius Biotech Inc, H2 2019
Pipeline by Shanghai Junshi Bioscience Co Ltd, H2 2019
Pipeline by Shanghai Mab Venture Biopharm Co Ltd, H2 2019
Pipeline by Sorrento Therapeutics Inc, H2 2019
Pipeline by Sound Biologics, H2 2019
Pipeline by Stcube Inc, H2 2019
Pipeline by Tikcro Technologies Ltd, H2 2019
Pipeline by Xencor Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019
Discontinued Products, H2 2019 (Contd..1), H2 2019
List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abeome Corp
- Aduro BioTech Inc
- Agenus Inc
- Akeso Biopharma Inc
- Alligator Bioscience AB
- AlphaMab Co Ltd
- Alpine Immune Sciences Inc
- Anaeropharma Science Inc
- Apollomics Inc
- AstraZeneca Plc
- BeyondSpring Inc
- Biocad
- Biosortia Pharmaceuticals
- BJ Bioscience Inc
- Bristol-Myers Squibb Co
- Cancure Ltd
- Cellective BioTherapy Inc
- Cold Genesys Inc
- CStone Pharmaceuticals Co Ltd
- DotBio Pte Ltd
- Five Prime Therapeutics Inc
- GigaGen Inc
- Harbour BioMed
- Hengenix Biotech Inc
- Hualan Biological Engineering Inc
- Immunocore Ltd
- Immunwork Inc
- Immutics Inc
- Innovent Biologics Inc
- Inovio Pharmaceuticals Inc
- JHL Biotech Inc
- Jiangsu Alphamab Biopharmaceuticals Co Ltd
- MacroGenics Inc
- Merck & Co Inc
- Momenta Pharmaceuticals Inc
- Nanjing Jinsirui Biotechnology Co Ltd
- OncoImmune Inc
- Premier Biomedical Inc
- Regeneron Pharmaceuticals Inc
- Replimune Ltd
- Serometrix LLC
- Shanghai Henlius Biotech Inc
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Mab Venture Biopharm Co Ltd
- Sorrento Therapeutics Inc
- Sound Biologics
- Stcube Inc
- Tikcro Technologies Ltd
- Xencor Inc
